Advertisement
FATE vs VCYT
Which Stock Would AI Choose? Fate Therapeutics (FATE) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- FATE is a clinical-stage, pre-revenue-adjacent biotech with a high-risk/high-reward profile, while VCYT is a profitable, commercial-stage diagnostics company with more established revenue streams.
- FATE has delivered sharp year-to-date gains off a low base but remains highly volatile, whereas VCYT shows steadier, fundamentally backed growth despite a recent pullback.
- The two companies operate in very different sub-sectors: cell-based immunotherapy versus genomic diagnostics, creating contrasting risk, momentum, and catalyst profiles.
- FATE depends on clinical trial milestones and cash runway, while VCYT depends on test adoption, reimbursement, and guideline inclusion.
- Relative performance diverges sharply: FATE has outperformed recently on momentum, while VCYT offers stronger fundamental stability and profitability.
- You can track FATE Major News and FATE Today's Price Move, as well as VCYT Major News and VCYT Today's Price Move, for ongoing coverage of these tickers.
- For a data-driven perspective on market positioning, explore Trending AI Robots.
Introduction
Comparing FATE and VCYT highlights two very different ways to gain exposure to the healthcare and life-sciences sector. One is a clinical-stage cell-therapy developer whose valuation is driven largely by pipeline progress and investor sentiment; the other is a commercial diagnostics provider generating recurring revenue and reported profitability. This stock comparison is most relevant for investors weighing speculative growth against more established fundamentals, as well as traders evaluating relative performance and market positioning across two companies with markedly different risk profiles.
FATE Overview and Recent Performance
Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company developing "off-the-shelf" cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell product candidates such as FT819, FT522, FT825, and FT836, targeting autoimmune diseases and cancer.
In recent weeks, FATE has shown substantial volatility, with sharp swings around its 20-day moving average and periods of multi-session declines followed by rebounds. The stock has risen well over 100% year to date, but this move reflects a low share price and a small market capitalization rather than revenue scale; trailing twelve-month revenue is minimal. Sentiment has been supported by clinical catalysts, including the initiation of the Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis and a related grant, while analyst price targets remain wide-ranging. Cash runway into 2028 provides a buffer, though ongoing operating losses and cash burn remain central considerations.
VCYT Overview and Recent Performance
Veracyte (VCYT) is a commercial-stage genomic diagnostics company whose portfolio includes the Afirma thyroid test, the Decipher Prostate genomic classifier, Prosigna for breast cancer, and Decipher Bladder, along with the emerging TrueMRD minimal residual disease platform.
Recent market activity for VCYT has been more measured than its biotech counterpart. The stock experienced a notable pullback over the past three months, followed by a partial rebound, and its year-to-date return is roughly flat-to-modestly positive. Underlying fundamentals have remained comparatively steady: testing volumes and revenues for Afirma and Decipher have grown at double-digit rates, the company raised full-year guidance, and it exited recent quarters with a debt-free balance sheet and substantial cash. Catalysts such as ASTRO conference data on Decipher, the U.S. launch of Prosigna, and updated NCCN (National Comprehensive Cancer Network) guideline mentions have supported sentiment, while reimbursement uncertainty and elevated valuation remain watchpoints.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a select subset earns a place in the curated Trending AI Robots section. This featured list is refreshed to reflect the bots best suited to current market conditions. Each bot operates with its own trading style, strategy, timeframe, performance record, and universe of tickers, so no two are alike. The result is a shortlist of signals and strategies that have demonstrated relevance in the present environment, rather than a one-size-fits-all approach. For traders evaluating names such as those in this comparison, exploring the Trending AI Robots page can offer a complementary, data-driven view of where momentum and positioning currently stand.
Head-to-Head Comparison
The core trade-off between FATE and VCYT is speculation versus execution. FATE has minimal commercial revenue and relies on clinical data readouts, with a high beta that makes it sensitive to broader biotech sentiment. Its growth drivers are binary: successful trial results and eventual regulatory and commercial milestones. In contrast, VCYT already monetizes its products, with growth tied to test volume, pricing, reimbursement, and guideline adoption.
Risk profiles diverge accordingly. FATE faces cash-burn and pipeline-execution risk but offers a larger potential upside if its therapies succeed. VCYT faces reimbursement, competition, and execution risk within an already commercialized business, with valuation leaving less room for error. On momentum, FATE has shown stronger recent relative performance, while VCYT demonstrates greater consistency in its underlying operating metrics. The two names also carry different sector exposures within healthcare: immunotherapy innovation versus diagnostics adoption.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely view the two names through different lenses. FATE displays stronger recent price momentum and upside from clinical catalysts, but its volatility and dependence on binary trial outcomes make its trend less consistent. VCYT offers a more stable, fundamentally supported profile with recurring revenue and profitability, though its recent pullback tempers near-term momentum. Probabilistically, the AI would tend to favor VCYT for trend reliability and fundamental positioning, while recognizing that FATE may carry greater speculative upside for momentum-oriented traders.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and VCYT is a Hold.
FATE in +3.98% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for FATE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 49 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VCYT's Stochastic Oscillator is remaining in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
VCYT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VCYT as a result. In 86 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for VCYT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
VCYT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VCYT crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.399) is normal, around the industry mean (67.298). P/E Ratio (16.778) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
FATE | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 75 | |
PRICE GROWTH RATING 1..100 | 62 | 89 | |
P/E GROWTH RATING 1..100 | 13 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FATE's Valuation (50) in the Biotechnology industry is in the same range as VCYT (70). This means that FATE’s stock grew similarly to VCYT’s over the last 12 months.
FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VCYT (100). This means that FATE’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as FATE (98). This means that VCYT’s stock grew similarly to FATE’s over the last 12 months.
FATE's Price Growth Rating (62) in the Biotechnology industry is in the same range as VCYT (89). This means that FATE’s stock grew similarly to VCYT’s over the last 12 months.
FATE's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for VCYT (97). This means that FATE’s stock grew significantly faster than VCYT’s over the last 12 months.
| FATE | VCYT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Advances ODDS (%) | 9 days ago 87% | 4 days ago 74% |
| Declines ODDS (%) | 1 day ago 90% | 11 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- VCYT’s TA Score: 4 bullish, 5 bearish.
Price Growth
FATE (@Biotechnology) experienced а -23.21% price change this week, while VCYT (@Medical Specialties) price change was -52.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.54%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was +38.26%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
VCYT is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+0.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement